Synack Commits to Supporting the Advancement of Women in Cybersecurity by Launching a Courageous Women in Security Initiative
New York Times reporter Jessica Bennett observed that the 2020 female Democratic candidates have largely avoided the phrase “glass ceiling”, prompting linguist Robin Lakoff to speculate that the phrase just “seems tired”. On the debate floor, action-oriented and empowering words like “persist” are replacing phrases like “glass ceiling” and the “stuck-ness” implicitly suggested by them. It’s not just in politics that women are intentionally working toward changing society’s perception of them in the workplace; it’s happening in cybersecurity too.
Today, women make up only 20% of the cybersecurity industry’s workforce. This largely untapped demographic could be the saving grace for an industry desperate for skilled labor and on pace to hit 3.5 million unfilled jobs by 2021 according to Cybersecurity Ventures. This is why today Synack launches their “Courageous Women CISO Initiative” which aims to encourage more women to enter the cybersecurity field; offer support by creating a strong network for women; and provide a platform for women to share their voice in the boardroom, across the aisles in policy, and from the podium at leading industry conferences. Synack will build upon efforts that aim to close the talent gap in other ways (like encouraging young women to enter into STEM fields) by empowering women to get to the forefront of cybersecurity innovation and lead the charge in making our organizations more secure. The company is also encouraging more women to apply to their elite Synack Red Team, the world’s best and most trusted crowd of ethical hackers.
“When the concept of harnessing a crowd of ethical hackers was novel, Synack found that women CISOs were 2x more likely to adopt crowdsourced security, which showed that female security leaders are willing to be bold and courageous when facing decisions that can make their organizations more secure. Cybersecurity is a field that needs more diversity in thought and action, and women are an underrepresented group. We need more female leaders in the field who have successfully navigated the industry to be examples and mentors to newcomers,” said Aisling MacRunnels, Synack CMO and Courageous Women CISO Initiative Chair.
Synack’s initiative aims to connect and empower security’s female change-makers through a series of networking events and opportunities to speak from the podium at industry-renowned conferences. Synack has partnered with Microsoft/M12, CyberWire and now Booz Allen Hamilton to host popular women’s networking events at Black Hat USA, RSA Conference, and Billington Cybersecurity Summit; later this week, the company will host their 3rd annual Women’s Brunch at Black Hat USA. Through these efforts, Synack aims to …
- Close the talent gap in cybersecurity by increasing the number of women entering the industry by 50% by 2022.
- Increase the number of women speaking at industry conferences, so that the percentage of female speakers is on par with the percentage of male speakers by 2022.
After the women’s lunch at the RSA Conference 2019, partners M12 and CyberWire said, “We had a great time with the Synack team today - if only every lunch could be filled with so many impressive women! A big thank you to our amazing hosts: Lisa Nelson, Microsoft Ventures and Aisling MacRunnels, Synack,” (M12), and “It is our pleasure to support and empower women in the field of cybersecurity!” (Cyberwire).
Synack’s Courageous Women CISO initiative was developed to bring female security leaders and executives together to support each other in having a bigger impact in their companies and industry. Through this initiative, Synack’s goal is to create an environment that fosters authentic conversations and provides a support network for women in cybersecurity. Let’s change the status quo in cybersecurity together - RSVP for upcoming events for women and learn more about Synack’s Courageous Women CISO Initiative here: https://go.synack.com/courageous-women-ciso.html.
About Synack
Synack, the most trusted crowdsourced security platform, delivers continuous and scalable penetration testing with actionable results. The company combines the world's most skilled and trusted ethical hackers with AI-enabled technology to create an efficient and effective security solution. Headquartered in Silicon Valley with regional offices around the world, Synack protects leading global banks, federal agencies, DoD classified assets, and close to $1 trillion in Fortune 500 revenue. Synack was founded in 2013 by former US Department of Defense hackers Jay Kaplan, CEO, and Dr. Mark Kuhr, CTO. For more information, please visit www.synack.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190805005459/en/
Contact information
Ellie McCardwell, Synack Communications
press@synack.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
